ELTP News Alert Elite Pharma Inc (ELTP) 0.3100 09/25/2014 21

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Elite Pharma Inc (ELTP) 0.3100 $ELTP

Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.

OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide a quarterly business update at 11:00 AM ET on Monday, August 18, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
GlobeNewswire - Tue Jul 15, 10:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating

Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide the year end business update at 12:00 PM ET on Tuesday, July 1, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
GlobeNewswire - Thu Mar 27, 11:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality Operations & Regulatory Affairs and has hired industry veteran, Barbara Ellison, to fill that role. Ms. Ellison has extensive experience in quality assurance, regulatory compliance, validation, performance optimization and quality control. Ms. Ellison will have overall responsibility for Elite's quality and regulatory functions including the Company's Quality Assurance and Compliance group and the Analytics and Quality Control group. Ms. Ellison will serve as a member of Elite's senior leadership team, reporting directly to Nasrat Hakim, Elite's President and Chief Executive Officer.

OTC Daily Alert Stock Watch - Elite Pharmaceuticals, Inc. (OTCQB: ELTP)
WorldStockWire - Tue Mar 25, 7:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Elite Pharmaceuticals submits site transfer application of Isradipine under FDA's CBE-30
M2 - Tue Mar 25, 5:55AM CDT
Controlled release products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the submission of a supplemental application with the US Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to its Northvale facility.

Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that on March 21, 2014, the Company filed a Changes Being Effected in 30 Days (CBE-30) supplemental application with the U.S. Food and Drug Administration (FDA) for the site transfer of manufacturing for Isradipine 2.5 mg and 5 mg tablets to Elite's Northvale facility.

Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process
ACCESSWIRE - Thu Mar 20, 11:29PM CDT
KeyCorp. (NYSE: KEY) - For an in-depth report on KeyCorp. follow: www.BullTrends.com/stockquote/KEY

Elite Pharmaceuticals awarded abuse deterrent technology patent in Canada, reflecting a rise in its intellectual property protection
M2 - Tue Mar 11, 6:09AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) reported on Monday the receipt of the Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" in Canada.

Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
GlobeNewswire - Mon Mar 10, 6:47AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
GlobeNewswire - Wed Mar 05, 6:30AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated in January 2014 for Elite's undisclosed abuse deterrent opioid product, ELI-200. The study results demonstrated Elite's product is bioequivalent to the branded drug based on pharmacokinetic measures including peak concentration (Cmax) and area under the curve (AUC) for opioid blood plasma levels. The study was a single dose, open label, partially randomized, three-way cross over study in healthy volunteers with 42 subjects under fasted conditions and 38 subjects under fed conditions.

Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
GlobeNewswire - Tue Feb 18, 6:00AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" ("Elite" (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

Legit Security Named as a Top Performer in Application Security

Updated Category News Views 210

Legit Security Recognized as a Leader in Application Security Legit Security, a leader in AI-native Application Security Posture Management (ASPM), has recently been acknowledged as a prominent player in the IDC MarketScape for ASPM. This achievement reflects the company's commitment to securing AI-powered application development processes. The IDC MarketScape report...

Continue Reading
Active Dental Transforms Patient Experience with New Website

Updated Category News Views 140

Active Dental Enhances Patient Accessibility with Unified Website Active Dental, a reputable family and general dentistry practice in the Dallas-Fort Worth metroplex, has launched a newly redesigned website that seamlessly integrates all five of its practice locations into a single, user-friendly digital platform. This significant upgrade aims to make appointment...

Continue Reading
Stork Club's Innovative Approach to Postpartum Depression Support

Updated Category News Views 229

Stork Club Innovates Reproductive Health Care Stork Club has recently launched an unprecedented initiative aimed at addressing postpartum depression (PPD) among working mothers. This pioneering program offers a seamless blend of digital diagnostics and therapy, leading to significant improvements in mental health outcomes. With up to 20% immediate relief from PPD symptoms...

Continue Reading
Investors Eye Class Action Against Fortrea Holdings, Inc.

Updated Category News Views 114

Understanding the Fortrea Holdings, Inc. Class Action Fortrea Holdings, Inc. (NASDAQ: FTRE) has gained attention due to rising investor concerns regarding its recent financial disclosures. Investors who have experienced losses over $100,000 are now presented with an opportunity to potentially lead a securities fraud lawsuit against the company. This lawsuit highlights...

Continue Reading
Alpha Tau Medical Plans Engagements at Key Healthcare Events

Updated Category News Views 91

Upcoming Participation in Major Healthcare Conferences Alpha Tau Medical Ltd., a leading developer of innovative cancer therapies, is gearing up for an exciting presence at significant healthcare conferences. The involvement of the Chief Financial Officer, Raphi Levy, at these events marks a pivotal opportunity for the company to showcase its groundbreaking...

Continue Reading